Prostate Cell News Volume 2.34 | Sep 16 2011

    0
    13

    Prostate Cell News 2.34, September 16, 2011

         In this issue: Publications | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Prostate Cell News on Twitter

    TOP STORY
    Dual Role of FoxA1 in Androgen Receptor Binding to Chromatin, Androgen Signaling and Prostate Cancer
    Researchers report a new paradigm for the forkhead protein FoxA1 action in androgen signaling. [EMBO J] Abstract

    ProstaCult_v04_645x110-ViewProto.jpg

    PUBLICATIONS (Ranked by Impact Factor of the Journal)

    LABORATORY RESEARCH

    Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
    Researchers report that taxanes inhibit ligand-induced androgen receptor (AR) nuclear translocation and downstream transcriptional activation of AR target genes such as prostate-specific antigen. [Cancer Res] Abstract

    Overexpression of Androgen Receptor Enhances the Binding of the Receptor to the Chromatin in Prostate Cancer
    The goal was to study the effect of androgen receptor (AR) overexpression on the chromatin binding of the receptor and to identify AR target genes that may be important in the emergence of castration-resistant prostate cancer. [Oncogene] Abstract

    Transforming Growth Factor β1 Increase of Hydroxysteroid Dehydrogenase Proteins is Partly Suppressed by Red Clover Isoflavones in Human Primary Prostate Cancer-Derived Stromal Cells
    Researchers suggest a pathway connecting overproduction of transforming growth factor-β with increased prostate-specific antigen in prostate cancer. [Carcinogenesis] Abstract

    Integrin αv Expression Is Required for the Acquisition of a Metastatic Stem/Progenitor Cell Phenotype in Human Prostate Cancer
    Researchers indicate that integrin αv expression is functionally involved in the maintenance of a highly migratory, mesenchymal cellular phenotype as well as the acquisition of a stem/progenitor phenotype in human prostate cancer cells with metastasis-initiating capacity. [Am J Pathol] Abstract

    The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness
    In this study, researchers systematically tested the hypothesis that inherited variations in the androgen and estrogen metabolic pathways may be associated with plasma levels of steroid hormones, or prostate cancer aggressiveness at diagnosis. [Cancer Prev Res] Abstract

    Dynamic Rewiring of the Androgen Receptor Protein Interaction Network Correlates with Prostate Cancer Clinical Outcomes
    Researchers characterized a large panel of novel androgen receptor-interacting proteins, through a combined proteomics/systems biology screen, that are of clinical relevance and could potentially serve as novel markers for diagnosis and prognosis of prostate cancer. [Integr Biol] Abstract

    Knockdown of Antizyme Inhibitor Decreases Prostate Tumor Growth In Vivo
    To determine whether antizyme inhibitor (AZI) functionally promotes prostate tumor growth, researchers made PC3M-LN4 (human) and AT6.1 (rat) cancer cell lines stably expressing short hairpin RNA to knockdown AZI. [Amino Acids] Abstract

    CLINICAL RESEARCH

    Single-Port Transvesical Enucleation of the Prostate for Benign Prostatic Hyperplasia with Severe Intravesical Prostatic Protrusion
    The objective of this study was to introduce the surgical techniques of a single-port transvesical enucleation of the prostate for enlarged prostates with severe intravesical prostatic protrusion presenting with lower urinary tract symptoms. [World J Urol] Abstract

    Toxicity Report of Once Weekly Radiation Therapy for Low-Risk Prostate Adenocarcinoma: Preliminary Results of a Phase I/II Trial
    Researchers conducted a multi-institution phase I/II trial of three-dimensional conformal radiation therapy for favourable-risk prostate cancer. [Radiat Oncol] Abstract

    Preoperative Weight Change and Risk of Adverse Outcome Following Radical Prostatectomy: Results From the Shared Equal Access Regional Cancer Hospital Database
    Researchers examined the relationship between weight change in the year before radical prostatectomy, biochemical recurrence and adverse pathology. [Prostate Cancer Prostatic Dis] Abstract

    ON191-AldefluorWebinar_645x110

    INDUSTRY NEWS

    Collaborative Agreement – ValiRx to Use Physiomics’ Virtual Tumor Technology to Accelerate Development of Promising Prostate Cancer Drug
    Physiomics Plc announced that it has signed a collaborative agreement with a wholly owned subsidiary of ValiRx plc, ValiPharma Limited relating to the further development and accelerated progress of VAL201, ValiPharma’s anti-cancer compound. [Physiomics plc] Press Release

    Impax Laboratories Confirms Patent Challenge Relating to Generic JALYN(R) 0.5 mg/0.4 mg
    Impax Laboratories, Inc. confirmed that it has initiated a challenge of the patents listed in connection with JALYN(R) (dutasteride and tamsulosin hydrochloride 0.5 mg/0.4 mg) capsules. [Impax Laboratories, Inc.] Press Release

    GE Healthcare to Invest $1 Billion in New Oncology Solutions
    General Electric (GE) Healthcare announced its plans to dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of biopharmaceuticals and for cancer research. [BusinessWire] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW VI Brazilian Congress on Stem Cells and Cell Therapy
    September 28-October 1, 2011
    Salvador, Brazil

    NEW 1st Annual Congress on Stem Cell Research 
    September 28-October 2, 2011 
    Sapanca, Turkey 

    NEW Select Biosciences STEMCELLS 2012 
    February 2-3, 2012 
    San Diego, United States 

    JOB OPPORTUNITIES

    Lab Technologist – Tissue Culture (STEMCELL Technologies)

    Scientist (iPSC) (STEMCELL Technologies)

    Contract Assay Service Technologist (STEMCELL Technologies)

    Research and Development Technologist (STEMCELL Technologies)

    Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

    Research Associate – Development (Precision Therapeutics, Inc.) 

    Postdoctoral Position – Stem Cells and Immunology (University of Connecticut)  

    Postdoctoral Fellow in Prostate Cancer Research (University of Texas Southwestern Medical Center)


    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

    Visit here to post your career opportunities.

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Prostate Cell News: Archives | Events | Contact Us